lipa

(redirected from LAL)
Also found in: Medical, Financial, Acronyms, Wikipedia.

li·pa

 (lē′pə)
n. pl. lipa
A Croatian unit of currency equal to 1/100 of the kuna.

[Serbo-Croatian.]

lipa

(ˈliːpə)
n, pl lipa
(Currencies) a monetary unit of Croatia worth one hundredth of a kuna

li•pa

(ˈli pə)
n., pl. -pa.
a monetary unit of Croatia.
References in periodicals archive ?
Previous BIR administrations had been hesitant in implementing the LAL because of its harsh features of demoting and even firing tax men for not meeting their collection targets that were were invariably described by tax experts as unrealistic or unreasonable, as evidenced by the bureau's failure to hit its collection target for years.
LAL deficiency is an autosomal recessive lysosomal storage disorder resulting in marked lysosomal accumulation of cholesteryl esters and triglycerides.
The MAA and the Biologics License Application (BLA) submitted to the US Food and Drug Administration include data from the company's global, randomized, double-blind, placebo controlled Phase 3 trial of sebelipase alfa in children and adults with LAL Deficiency & the Phase 2/3 trial of sebelipase alfa in infants with LAL Deficiency.
The LAL discussion will touch on the project's "origins, how it selects its titles, and the challenge of making this rich literary tradition accessible to contemporary readers.
About two years ago, FDA updated its original 1987 guidelines covering the use of LAL testing for in-product release in an LAL-testing Q&A (http://www.
Sebelipase alfa (SBC-102) is a recombinant form of the human LAL enzyme under development by Synageva as an enzyme replacement therapy for LAL Deficiency, a lysosomal storage disorder (LSD).
About ARISE: A global Phase 3 trial of sebelipase alfa in children and adults with late onset LAL Deficiency
Children and adults with late onset LAL Deficiency can suffer from serious liver complications and accelerated atherosclerosis," said Manisha Balwani, MD, MS, Assistant Professor of Genetics and Genomic Sciences and Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, and principal investigator in the study.
The T2Endotoxin assay utilizes T2MR technology to sense the formation of the LAL gel, similar to blood clotting, which enables higher sensitivity, faster detection and lower reagent consumption.
SBC-102 is being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD), and is a recombinant form of the human LAL enzyme.
SBC-102 is being developed as an enzyme replacement for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD), and is a recombinant form of the human LAL enzyme.